



Does your child with NF1 have muscle weakness and fatigue?

If so, learn about the L-carnitine study and find out if your child can participate.

This study is a clinical research study designed to enroll children who have a rare disease called Neurofibromatosis 1 (NF1). This project has been approved by the NSLHD Human Research Ethics Committee-**2024/ETH00028. Supplement Treatment Evaluation of L-CarNitine for Muscle Fatigue and Weakness in Children with Neurofibromatosis Type 1 (STrENgTh)** is a research study testing a new treatment for muscle fatigue and weakness brought about by NF1. The new treatment is called L-carnitine.

The STRENGTH study is enrolling NF1 patients aged 8-12 years

Use the contact information below or scan the QR code to find out if your child qualifies:

Clinical Associate Professor Yemima Berman
Head, Department of Clinical Genetics
Royal North Shore Hospital,
Reserve Road, St Leonards NSW 2065

📞 02 9463 1727

✉️ NSLHD-Neurofibromatosis@health.nsw.gov.au

🌐 <http://www.nslhd.health.nsw.gov.au>

Study participants receive at no cost:

- Access to a study medicine
- Study assessments and checks
- The opportunity to share your experience and contribute to research on NF1



www.redcap.link/nfstrength